Novel biotechnology drug platform CytoProtect©
Robust drug pipeline:
1. Hepatitis (A, B, C and D) drug, already on the market in the CIS under Mellozan® brand name
2.Cerebrovascular attack drug, very close to market
3.Ischemic heart disease
4.Tuberculosis
5.Cancer
6.Alzheimer's
7.AIDS
8.Fertility
9.Regenerative medicine drug for wound healing and rehabilitation after complex surgeries
10. Diabetes
CytoProtect© is a biotechnology drug platform based on the biotechnological synthesis of nearly 600 compounds derived from bee honey. Drugs developed with this platform do not contain chemical additives, are non-toxic, not mutagenic, non allergenic (in rear cases provoke an increase in body temperature due to activation of immediate immune response). The main property of the drugs developed with CytoProtect© platform - expressed cytoprotective effect. INFREDpharm drug pipeline includes 1 drug and 9 drug candidates.
*Preclinical and early clinical trials (groups of 20-200 patients), conducted in clinics of several countries: mainly Slovakia, Moldova, Tajikistan.